Merck KGaA’s AI Platform Architect On Redefining The Drug Discovery Process

 
• By Anju Ghangurde

The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.

Ashwini Ghogare, Head of AI and Automation in Drug Discovery at Merck KGaA’s life science business

More from Business

More from Digital Technologies